Icahn School of Medicine at Mount Sinai

NIH partners with 11 biopharmaceutical companies on cancer immunotherapy strategies

Friday, October 13, 2017

The NIH and 11 biopharmaceutical companies launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers—standardized biological markers of disease and treatment response—to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the Foundation for the National Institutes of Health (FNIH), with the Food and Drug Administration serving in an advisory role. 

[Read More]

Four NCI Cancer Centers form Consortium, collaborate with Celgene

Tuesday, June 28, 2016

The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai announced the establishment of a research consortium focused on accelerating the discovery and development of novel cancer therapeutics and diagnostics for the benefit of patients.

[Read More]

Digital clinical research is nearing a tipping point

Monday, January 18, 2016

The Pulse on Global Trials by Matthew Howes

Since I started writing this column two years ago, clinical research has seen modest improvements in failure rates of late stage trials, but for the most part drug development remains unnecessarily expensive and inefficient. 

[Read More]

DBV Technologies adds Dr. Hugh Sampson as chief scientific officer

Monday, June 29, 2015

DBV Technologies, a clinical-stage specialty biopharmaceutical company, has appointed Dr. Hugh Sampson chief scientific officer. In partnership with Dr. Dupont, chairman of the company’s scientific advisory board, Sampson will lead DBV’s research team, pursuing new Viaskin applications for the treatment of food allergies, while also supporting the company’s clinical development teams.

[Read More]

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Monday, March 23, 2015

Apple has taken a key step this month toward helping to improve patient recruitment for medical studies with ResearchKit, a new iPhone-based medical software platform researchers can use to de­sign and administer app-based observational studies. ResearchKit will help both doctors and researchers gather patient data frequently and more accurately track disease signs using sen­sors that are on the iPhone.

[Read More]

NIH launches Illuminating the Druggable Genome to find potential drug targets

Wednesday, October 29, 2014

NIH has announced a new collaborative initiative to improve human health by exploring poorly understood genes that have the potential to be modified by medicines. The effort is part of an NIH Common Fund three-year pilot project called Illuminating the Druggable Genome (IDG). For the initial phase of the program, NIH has allocated $5.8 million to eight institutions and for intramural resources.

[Read More]

NIH awards $64M for the understanding of cell pathways, development of new therapies

Tuesday, September 16, 2014

Building on a successful three-year pilot project, the NIH has awarded more than $64 million to six research institutions to create a database of human cellular responses, the Library of Integrated Network-based Cellular Signatures (LINCS).  Discovering such cell responses will improve scientists’ understanding of cell pathways and aid in the development of new therapies for many diseases.

[Read More]